Skip to content
AwardedSpainGoods€2,434,682

1ª Prorroga (adelantada) Suministro de NATALIZUMAB jeringa (TYSABRI) y DIROXIMEL FUMARATO cápsula (VUMERITY) de distribución exclusiva con destino al Servicio de Farmacia del Hospital Clínico San Carlos de Madrid

Published
Published 27 March 2025

Overview

1ª Prorroga (adelantada) Suministro de NATALIZUMAB jeringa (TYSABRI) y DIROXIMEL FUMARATO cápsula (VUMERITY) de distribución exclusiva con destino al Servicio de Farmacia del Hospital Clínico San Carlos de Madrid

Key details

Country
Spain
Status
Awarded
Category
Goods
Estimated value
€2,434,682
Procedure
Direct
Published
27 March 2025
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
€325,570
Award date
26 March 2025
Contract period
— → 28 February 2030
Winner
  • BIOGEN SPAIN S.L.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    27 March 2025

  2. Contract Award Notice

    26 April 2024

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: 1ª Prorroga (adelantada) Suministro de NATALIZUMAB jeringa (TYSABRI) y DIROXIMEL FUMARATO cápsula (VUMERITY) de distribución exclusiva con destino al Servicio de Farmacia del Hospital Clínico San Carlos de Madrid — won by BIOGEN SPAIN S.L. — Skim